Literature DB >> 8834422

Acute tolerance to subjective but not cardiovascular effects of d-amphetamine in normal, healthy men.

L H Brauer1, J Ambre, H De Wit.   

Abstract

This is a descriptive report on the relationship between the pharmacokinetics and pharmacodynamics of d-amphetamine in healthy, normal volunteers. Six men, aged 22 to 31, attended two experimental sessions during which they received single oral doses of 20 mg of d-amphetamine. Plasma levels of drug and measures of drug effect were collected predrug and at regular intervals for 24 hours after drug administration. Plasma drug levels peaked at 4 hours and remained at detectable levels for 24 hours after drug administration. Subjective ratings, including "feel drug" and "feel high" peaked at 1 1/2 to 2 hours and returned to baseline levels by 3 to 4 hours. Evaluation of phase plots (i.e., drug effect vs. drug concentration) indicated that acute tolerance developed to the subjective but not to the cardiopressor effects of d-amphetamine. This finding implies that individuals who repeatedly administer the drug to maintain certain levels of subjective effects may increase plasma drug levels and physiologic effects to toxic levels.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8834422     DOI: 10.1097/00004714-199602000-00012

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  20 in total

1.  Risperidone diminishes cocaine-induced craving.

Authors:  Richard De La Garza; Thomas F Newton; Ari D Kalechstein
Journal:  Psychopharmacology (Berl)       Date:  2004-09-25       Impact factor: 4.530

2.  The effects of dexamphetamine on simulated driving performance.

Authors:  B Y Silber; K Papafotiou; R J Croft; E Ogden; P Swann; C Stough
Journal:  Psychopharmacology (Berl)       Date:  2004-12-22       Impact factor: 4.530

3.  Comparison of the behavioral and cardiovascular effects of intranasal and oral d-amphetamine in healthy human subjects.

Authors:  Joshua A Lile; Shanna Babalonis; Cleeve Emurian; Catherine A Martin; Daniel P Wermeling; Thomas H Kelly
Journal:  J Clin Pharmacol       Date:  2010-07-29       Impact factor: 3.126

4.  Variability in paralimbic dopamine signaling correlates with subjective responses to d-amphetamine.

Authors:  Christopher T Smith; Linh C Dang; Ronald L Cowan; Robert M Kessler; David H Zald
Journal:  Neuropharmacology       Date:  2016-05-10       Impact factor: 5.250

Review 5.  Pharmacokinetic-Pharmacodynamic (PKPD) Analysis with Drug Discrimination.

Authors:  S Stevens Negus; Matthew L Banks
Journal:  Curr Top Behav Neurosci       Date:  2018

6.  Negative allosteric modulation of GABAA receptors inhibits facilitation of brain stimulation reward by drugs of abuse in C57BL6/J mice.

Authors:  Matthew E Tracy; Matthew L Banks; Keith L Shelton
Journal:  Psychopharmacology (Berl)       Date:  2015-11-27       Impact factor: 4.530

7.  Relationship between discriminative stimulus effects and plasma methamphetamine and amphetamine levels of intramuscular methamphetamine in male rhesus monkeys.

Authors:  Matthew L Banks; Douglas A Smith; David F Kisor; Justin L Poklis
Journal:  Pharmacol Biochem Behav       Date:  2015-12-03       Impact factor: 3.533

Review 8.  Cardiovascular effects of atomoxetine in children, adolescents, and adults.

Authors:  Joachim F Wernicke; Douglas Faries; Donald Girod; Jeffrey Brown; Haitao Gao; Douglas Kelsey; Humberto Quintana; Robert Lipetz; David Michelson; John Heiligenstein
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 9.  Striatal ups and downs: their roles in vulnerability to addictions in humans.

Authors:  Marco Leyton; Paul Vezina
Journal:  Neurosci Biobehav Rev       Date:  2013-01-16       Impact factor: 8.989

10.  Residual effects of intranasal methamphetamine on sleep, mood, and performance.

Authors:  Audrey Y Perez; Matthew G Kirkpatrick; Erik W Gunderson; Gina Marrone; Rae Silver; Richard W Foltin; Carl L Hart
Journal:  Drug Alcohol Depend       Date:  2007-12-19       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.